Dust Mite Allergy

Sublingual immunotherapy tablets improved quality of life for patients with allergic rhinitis with and without conjunctivitis, according to a review published in The Journal of Allergy and Clinical Immunology: In Practice.

A healthy, adolescent boy is seen for recurrently awakening with pruritic, urticarial-like lesions between his upper thighs extending to his mid-thorax.

A cell protein known as LMAN1 plays a role in responses to house dust mite, opening potential avenues for new treatments for these and other allergies, according to a study published in Cell Reports.

Subcutaneous immunotherapy for house dust mite allergy may slightly protect patients against SARS-CoV-2 infection, especially after the dose-escalation phase, according to a letter published in Clinical and Translational Allergy.

Allergy immunotherapy is effective in achieving long-term results for allergic rhinitis in real-world treatment, according to a study published in The Journal of Allergy Clinical Immunology.

Early efficacy in treatment may predict clinical response to subcutaneous immunotherapy for allergic rhinitis due to house dust mite allergy at 3 years, according to a letter published in Clinical and Translational Allergy.

SAN ANTONIO — Kombucha may play a role in stabilizing mast cells, but it does not act as an antihistamine in treating allergic reactions, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual meeting.

Adolescents aged 12 to 17 years with allergic rhinitis induced by house dust mites now can take a sublingual immunotherapy tablet approved by the FDA after review of multiple trials in this age group.

The FDA approved house dust mite allergen extract tablet for sublingual immunotherapy treatment of house dust mite-induced allergic rhinitis in patients aged 12 to 17 years, according to a press release from the manufacturer.

Healio compiled the most-read news in allergy, asthma and immunology posted in November.